Table of Contents

company-logo

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Minerva Neurosciences Dividend Announcement

• Minerva Neurosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Minerva Neurosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Minerva Neurosciences Dividend History

Minerva Neurosciences Dividend Yield

Minerva Neurosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Minerva Neurosciences stock? Use our calculator to estimate your expected dividend yield:

Minerva Neurosciences Financial Ratios

P/E ratio-5.46
PEG ratio0.07
P/B ratio-0.00
ROE0.00%
Payout ratio0.00%
Current ratio6.23
Quick ratio6.23
Cash Ratio5.92

Minerva Neurosciences Dividend FAQ

Does Minerva Neurosciences stock pay dividends?
Minerva Neurosciences does not currently pay dividends to its shareholders.
Has Minerva Neurosciences ever paid a dividend?
No, Minerva Neurosciences has no a history of paying dividends to its shareholders. Minerva Neurosciences is not known for its dividend payments.
Why doesn't Minerva Neurosciences pay dividends?
There are several potential reasons why Minerva Neurosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Minerva Neurosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Minerva Neurosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Minerva Neurosciences a dividend aristocrat?
Minerva Neurosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Minerva Neurosciences a dividend king?
Minerva Neurosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Minerva Neurosciences a dividend stock?
No, Minerva Neurosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Minerva Neurosciences stocks?
To buy Minerva Neurosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Minerva Neurosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.